🏢 公司NewsroomANIPCodex · 实盘不做把握 9/10
北京时间·🕒 发布 18:51:09时区推断·⟳ 抓取 18:55:53·⚡ 决策 07-24 18:56:31 +38s·95.0 天前
ANI Pharmaceuticals宣布将于8月7日披露二季度业绩并召开电话会
本次只是财报披露时间和电话会安排通知，未包含收入、利润、指引、产品进展或监管结果等新增经营信息。
📄 原文ANIP↗ 原文
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET Content Import 0…
不做 ANI Pharmaceuticals（ANIP.US）
例行财报电话会日程通知，没有业绩数字、指引修正或产品/监管新增事实，当前不形成可回测同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-24 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是财报披露时间和电话会安排通知，未包含收入、利润、指引、产品进展或监管结果等新增经营信息。
主要风险
- 真正可交易信息需等2026年8月7日二季度业绩发布后再研判。
原文全文
展开原文 · 2,232 字
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
Content Import
07/24/2026
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
07/24/2026
General
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
To view the webcast, please click here . Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com , under the “Investors” section. A replay of the event will remain accessible for up to one year.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com
Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
SOURCE: ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer,
Content Import
07/24/2026
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
07/24/2026
General
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
To view the webcast, please click here . Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com , under the “Investors” section. A replay of the event will remain accessible for up to one year.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com
Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
SOURCE: ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET. Nikhil Lalwani, President and Chief Executive Officer,
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。